ArticleMaterials today. Bio2026
Development of nanoparticles loaded with D-mannose for topical treatment to alleviate skin aging via rescuing SIRT1 from degradation.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin aging is a complicated biological process, greatly interrupting skin physical function and increasing the risk of aging-associated skin diseases, therefore, drugs or treatment to delay or even reverse this process is in urgent need. D-mannose, a monosaccharide metabolite existing in human body and nature, has been demonstrated as a protential beneficial supplementation in clinical practice. However, whether D-mannose could alleviate skin aging remains unclear. Based on our previous study, we initially investigated the effect of topical supplementation of D-mannose on skin aging and found that it markedly rescued the senescent phenotype and recovered extracellular matrix disposition in the aging skin mice model. Considering that exogenous D-mannose predominantly eneters in lysosomes and subsequently exerts its biological functions, we therefore constructed a nanomaterial-loaded-D-mannose (MSN-B-Man) which could deliver D-mannose to lysosomes precisely. Furthermore, we observed prolonged skin retention of D-mannose and stronger anti-senescent effect upon topical application of MSN-B-Man compared with D-mannose alone. Mechanistically, D-mannose, cargo of MSN-B-Man, could physically bound with SIRT1 to prevent SIRT1 degradation in skin fibroblast during senescence, thus activating autophagy and further suppressing skin aging. Therefore, our present results first time unveil a novel protective role and underlying mechanisms of D-mannose during the skin aging course, highlighting the potential application of topical MSN-B-Man administration in alleviating skin aging and skin aging-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.